BLACK WEEKSLahvičky −15 % · kity −10 % · ostatní −5 %s kódemDoprava po Německu zdarma od 200 €

Tato stránka byla přeložena automaticky a může obsahovat chyby. Jste rodilý mluvčí? Rádi uvítáme vaši zpětnou vazbu a opravy.Poslat zpětnou vazbu

The Peptide Desk The Peptide Desk

Tyto informace slouží výhradně k výzkumným a vzdělávacím účelům. Nejde o lékařská doporučení. Produkty nejsou schváleny k použití u lidí. Se zdravotními otázkami se obraťte na lékaře.

Lexikon

Armodafinil (Nuvigil, Waklert)

The R-enantiomer of modafinil, not stronger but longer: same peak, flatter decline and a longer afternoon.

7 min read 10 sources

Large blue 3D molecule model with one yellow, one light blue and two white atoms above a white podium with a glowing rim in a bright lab
Approved · in the USA since 2007

Summary

At a glance

Sources checked on 26 Oct 2026

Half-life
~15 hours

single-phase decline, steady level after about 7 days7

Exposure per milligram
+40 %

area under the curve versus modafinil, same peak, longer afternoon3

Sleep latency on the night shift
5.3 minutes

2.3 minutes before, 2.8 minutes with placebo at the end1

Headache
17 %

most common side effect in the approval trials, 9 percent with placebo7

Long-term study of 12 months or more
743 participants

the effect was maintained, 13 percent stopped because of side effects5

  • Armodafinil is the R-enantiomer of modafinil, the more slowly cleared half of the racemate. It inhibits the dopamine transporter and so raises dopamine between nerve cells.69
  • Peak and half-life match modafinil, but levels fall in a single phase and more slowly. Milligram for milligram total exposure was 33 to 40 percent higher, especially in the afternoon.3
  • In shift work disorder sleep latency on the night shift rose from 2.3 to 5.3 minutes, in narcolepsy the time patients stayed awake lengthened versus placebo.12
  • Armodafinil induces the liver enzyme CYP3A4 and inhibits CYP2C19. The most common side effect is headache, dose-dependent.47
  • Armodafinil has been approved in the USA since 2007 for sleepiness in sleep apnoea, narcolepsy and shift work disorder. Everything here is research, not a recommendation.87
Profil

Updated October 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~15 hours

Half-life ~15 hours
After 30 hours: 25 %
Hour 15 · 50 %Hour 30 · 25 %Hour 45 · 12.5 %Hour 75 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
Eugeroic

wakefulness promoter, R-enantiomer of modafinil

Use
Oral

1x per waking phase, in the morning or about 1 hour before the shift

Half-life
About 15 hours

single-phase decline

Onset
Peak plasma level after about 2 hours fasted, 2 to 4 hours later with food
Equivalence
150mg corresponds roughly to 200mg modafinil in total exposure
Status
Clinically approved

narcolepsy, sleep apnea, shift work disorder, WADA S6 prohibited in competition

Sizes
150 to 250 mg

3 sizes in the shop

Obsah 15 sections
  1. V kostce
  2. What is armodafinil?
  3. How it works
  4. R-enantiomer versus racemate: the difference is in the curve
  5. Pharmacokinetics: timing and food
  6. Use and dosing
  7. What the research shows
  8. Stav výzkumu
  9. Interactions: CYP3A4 and hormonal contraception
  10. Side effects
  11. Storage
  12. Příbuzné látky
  13. Časté dotazy
  14. Pojmy
  15. Zdroje

What is armodafinil?

Armodafinil is the R-enantiomer of modafinil. Modafinil is a racemate, a 1:1 mix of two mirror-image molecules that the body clears at different speeds: the S-enantiomer leaves plasma roughly three times faster than the R-enantiomer. Armodafinil keeps only the slower-clearing half, so it is not a new substance but one half of a familiar one.

Clinically, armodafinil (brand name Nuvigil, sold in India among others as Waklert) is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnea and shift work disorder. Like modafinil it belongs to the eugeroics, the wakefulness promoters. It is not an amphetamine derivative. The pharmacokinetic rule of thumb: 150mg armodafinil corresponds roughly to 200mg modafinil in total exposure.

This information is for research and educational purposes only. No medical advice.

How it works

The mechanism is the same as for the racemate and still not resolved in every detail. At its core sits inhibition of the dopamine transporter (DAT): armodafinil blocks dopamine reuptake into the neuron and thereby raises extracellular dopamine. Unlike amphetamines it does not push dopamine out of the storage vesicles, which is what gives it the calmer character. In the transporter work by Loland and colleagues (Biological Psychiatry 2012) the R-enantiomer bound DAT with roughly three times the affinity of the S-enantiomer, inhibited dopamine uptake far less potently than cocaine and raised dopamine in the nucleus accumbens more modestly but for longer.

On top of that come indirect effects on the hypothalamic wake systems: orexinergic and histaminergic pathways are activated, cortical catecholamines rise, GABA falls. Those are the circuits that run the sleep-wake cycle rather than general drive. Subjectively the result is closer to "not tired" than to "wired".

Where it acts

Where armodafinil acted in studies

Tap a point or a card. Colour = dopamine transporter, grey = observed in studies.

  1. Brain

    Inhibits dopamine reuptake, less potently than cocaine, dopamine rises for longer (mice)6

    DAT
  2. Heart and circulation

    Blood pressure on average 3.6/2.3 mmHg and pulse 6.7 beats per minute higher (long-term study)5

    Observed in trials
  3. Liver

    Induces CYP3A4 and inhibits CYP2C19, levels of other drugs change4

    Observed in trials
  4. Skin

    Rash dose-dependent, severe skin reactions rarely described7

    Observed in trials

Targets in the ChEMBL database9

Compound CHEMBL1201192 (Armodafinil): one recorded mechanism, Inhibitor, direct binding.

Dopamine transporter
Gene
SLC6A3
UniProt
Q01959
ChEMBL
CHEMBL238
Action
Inhibitor, direct binding
Glass nerve cell junction (synapse) with glowing golden particles in the gap, blue 3D molecules docking onto the cell wall
Less dopamine reuptake in the synaptic gap. Symbolic image.

R-enantiomer versus racemate: the difference is in the curve

The most common misconception is that armodafinil is the stronger version of modafinil. It is not, at least not at the peak. Darwish and colleagues (Clinical Drug Investigation 2009) pooled three single-dose studies in healthy adults and normalized everything to 200mg. Both drugs had a single-dose terminal half-life of about 13 hours (the prescribing information puts armodafinil at about 15 hours), similar peak concentrations and a similar time to peak.

The difference appears after the peak. Modafinil declines in two phases because its S-enantiomer disappears quickly in the first hours. Armodafinil declines in a single, flatter phase. Milligram for milligram, exposure (AUC) was 33 to 40 percent higher with armodafinil. Plasma levels late in the day sat clearly above those of modafinil. In practice: same peak, longer afternoon. That is why armodafinil was the compound of choice in shift work research. It is also exactly where its risk to sleep comes from.

Comparison

Modafinil and armodafinil compared

The modafinil and armodafinil entries in the TPD lexicon, as described there. Tap a card to open its entry.

R-enantiomer, single-phase decline Armodafinil (Nuvigil, Waklert) DAT
Racemate of the R and S forms Modafinil (Provigil, Modalert) DAT
Armodafinil as a branded tablet Waklert (armodafinil 150mg, Sun Pharma) DAT
Modafinil as a branded tablet Modalert (modafinil by Sun Pharma) DAT

Simplified: all act on the dopamine transporter. The R-enantiomer bound about three times more tightly than the S-enantiomer and stays in the blood longer. 63

Pharmacokinetics: timing and food

Taken on an empty stomach, armodafinil peaks after about 2 hours. A high-fat meal pushes the peak back by 2 to 4 hours without changing total absorption. The mean elimination half-life is around 15 hours. Steady state is reached within about 7 days of daily dosing, with exposure then about 1.8 times above a single dose. Kinetics are linear from 50 to 400mg, so double the dose means double the exposure (prescribing information).

From this follows the single most important rule: dose early or not at all. A dose at noon still carries well over half its peak level at midnight. Unlike modafinil there is no fast-clearing half that eases the evening a little. Taking it with a meal shifts the peak further into the afternoon on top of that.

Exposure is higher in older adults, where the prescribing information advises lower doses. In severe hepatic impairment the dose should be reduced, because elimination runs through the liver.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
White folding box with the TPD logo next to a blister with ten white tablets and two loose tablets on a bright lab bench
Tablet in a blister, according to the entry early in the day. Symbolic image.

What the research shows

The strongest evidence is in shift work. Czeisler and colleagues (Mayo Clinic Proceedings 2009) randomized 254 night shift workers with shift work disorder to 150mg armodafinil or placebo, taken 30 to 60 minutes before each shift for 12 weeks. Mean sleep latency during the night shift rose from 2.3 to 5.3 minutes on armodafinil versus 2.4 to 2.8 minutes on placebo. Standardized memory and attention tests improved. Daytime sleep was not disturbed on polysomnography.

In narcolepsy, Harsh and colleagues (Current Medical Research and Opinion 2006) compared 150mg, 250mg and placebo in 196 patients over 12 weeks. Both doses significantly lengthened sleep latency on the Maintenance of Wakefulness Test and improved memory, attention and fatigue. The gap between 150 and 250mg was small: plus 1.3 versus plus 2.6 minutes, against a drop of 1.9 minutes on placebo.

Long-term data come from the open-label extension by Black and colleagues (Journal of Clinical Sleep Medicine 2010): 743 patients for at least 12 months at 50 to 250mg per day, with the effect maintained, 13 percent discontinuing for adverse events and moderate rises in blood pressure and heart rate. What is missing is evidence for cognitive enhancement in rested healthy people. The healthy-volunteer studies of armodafinil were almost all run under sleep deprivation. For the racemate, meta-analyses show only a small effect, as described in the modafinil entry.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Sleep latency during the night shift1

Mean minutes until falling asleep in the sleep lab

Baseline1
Placebo 2.4 min
Armodafinil 2.3 min
Final visit1
Placebo 2.8 min
Armodafinil 5.3 min

254 night shift workers, taken 30 to 60 minutes before the shift. Memory and attention improved and daytime sleep in the sleep lab was not disturbed. Clinical condition improved in 79 versus 59 percent.

Time staying awake in the daytime test2

Change from baseline, in minutes

Wakefulness latency (9 am to 3 pm)2
Placebo -1.9 min
Lower study dose +1.3 min
Higher study dose +2.6 min

196 patients. At least minimally improved in overall clinical impression were 69 and 73 percent versus 33 percent with placebo. Memory, attention and fatigue improved.

Total exposure milligram for milligram3

Area under the curve, difference in percent (modafinil = 0)

Up to the last measurement3
Modafinil (comparison) 0%
Armodafinil 33%
Extrapolated to infinity3
Modafinil (comparison) 0%
Armodafinil 40%

Three single-dose studies in healthy adults, normalised to the same amount. Half-life of both about 13 hours, similar peak. Modafinil fell in two phases because its S part disappears quickly.

Levels of probe drugs with armodafinil4

Change in area under the curve, in percent

Oral midazolam (CYP3A4)4
Armodafinil -32%
Intravenous midazolam (CYP3A4)4
Armodafinil -17%
Omeprazole (CYP2C19)4
Armodafinil +38%
Caffeine (CYP1A2)4
Armodafinil 0%

77 healthy adults in three studies. Armodafinil is a moderate inducer of CYP3A4 and a moderate inhibitor of CYP2C19, it had no effect on CYP1A2.

Glass brain model seen from above, surrounded by Petri dishes, a white wall clock and a pipette on a white background
Studies on shift work, narcolepsy and sleep apnoea. Symbolic image.

Research status

Where the research stands

Armodafinil has been approved since 2007. On ClinicalTrials.gov 62 trials list armodafinil among their interventions. Shown are the phase 3 trials in the three approved uses, the long-term study and later phase 3 trials in other areas. As of 26 Oct 2026. 10

  1. Preclinical Binding to the dopamine transporter, comparison of the enantiomers
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 10 trials, 9 completed, 1 stopped early
  5. Approval in the USA since 2007
4,398 participants in phase 3 Approved: in the USA since 15 June 2007 (NDA 021875) for excessive sleepiness in sleep apnoea, narcolepsy and shift work disorder, ChEMBL lists armodafinil with phase 4 as the highest phase.8
Show all 10 phase 3 trials on a timelineHide timeline 9 completed 0 running 1 stopped early 3 with results
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026, grey = stopped early.

Interactions: CYP3A4 and hormonal contraception

Armodafinil induces CYP3A4 and inhibits CYP2C19. Darwish and colleagues (Clinical Pharmacokinetics 2008) measured this in three probe studies in 77 healthy adults: after at least 22 days on 250mg armodafinil, midazolam exposure fell by about 17 percent after intravenous and 32 percent after oral dosing, while caffeine (CYP1A2) was unchanged. Omeprazole was tested separately, with a single 400mg dose of armodafinil given 2 hours before the omeprazole. Omeprazole exposure rose by about 38 percent.

In practice: substances cleared through CYP3A4 become weaker. Hormonal contraceptives are among them. The prescribing information states that hormonal contraception is less reliable during use and for about one month afterwards. In the other direction, levels of CYP2C19 substrates such as omeprazole, diazepam or phenytoin rise. Anyone using such a substance should take that question to a doctor.

Side effects

  • Serious skin reactions: rare but serious. Rash requiring hospitalization, up to Stevens-Johnson syndrome and toxic epidermal necrolysis, is documented for armodafinil and modafinil, along with multi-organ hypersensitivity (DRESS) and angioedema. Any new rash, any blistering and any involvement of mouth, eyes or mucous membranes is a reason to stop and a case for medical assessment. In the pooled registration trials rash occurred in 4 percent on 250mg and 1 percent on 150mg.
  • Headache: by far the most common, 17 percent versus 9 on placebo. It is also dose-dependent (23 percent on 250mg, 14 on 150mg).
  • Insomnia: 5 percent in the trials, almost always a question of timing. With armodafinil the flatter decline makes this weigh heavier than with modafinil.
  • Nausea, dizziness, dry mouth, anxiety, diarrhea: regularly reported, mostly mild to moderate.
  • Circulation: in the long-term study blood pressure rose by an average of 3.6/2.3 mmHg and heart rate by 6.7 beats per minute, mostly within the first three months. Anyone with blood pressure issues should keep measuring.
  • Mental state: anxiety, agitation, nervousness and depressed mood led to discontinuation more often than on placebo. With a history of psychosis, depression or mania the prescribing information calls for particular caution.
  • Abuse potential: lower than with amphetamines, but not zero. Armodafinil is a Schedule IV controlled substance in the US. Cases of abuse are documented.

Tolerability

Side effects in the approval trials

From the US label: pooled trials in sleep apnoea, narcolepsy and shift work. The study arms are named relative to each other.

9 of 100 Placebo
14 of 100 Lower study dose
23 of 100 Higher study dose
Event PlaceboLower study doseHigher study dose
Headache7 9%14%23%
Nausea7 3%6%9%
Insomnia7 1%4%6%
Dizziness7 2%0%0%
Anxiety7 1%0%0%
Stopped because of side effects7 4%0%0%

Armodafinil arm = both study doses combined (645 versus 445 with placebo). Rash occurred in 4 percent at the higher study dose and 1 percent at the lower one. Severe skin reactions are rare but described.7

Storage

Store dry, at room temperature and protected from light. Leave tablets in the blister until you need them and keep them out of reach of children. Use split tablets promptly rather than keeping halves around for weeks.

Three white bottles on a bright shelf next to a folded light blue towel
Store dry, at room temperature and out of reach of children. Symbolic image.

Related

Related compounds

Same targets: all in the TPD lexicon.

FAQ

Common questions about Armodafinil (Nuvigil, Waklert)

Short answers, each backed by the sources below.

What is armodafinil approved for?

In the USA since June 2007 to improve wakefulness in adults with excessive sleepiness from obstructive sleep apnoea, narcolepsy or shift work disorder. In sleep apnoea it does not replace treatment of the airway.87

Is armodafinil stronger than modafinil?

Not at the peak. Half-life and peak level were the same after single doses, both about 13 hours. Armodafinil, however, falls in a single phase and more slowly, so total exposure per milligram was 33 to 40 percent higher. Above all this means more drug in the afternoon and evening.3

What did the shift work study show?

254 night shift workers took armodafinil or placebo before the shift for 12 weeks. Sleep latency at night rose from 2.3 to 5.3 minutes, with placebo only from 2.4 to 2.8. Memory and attention improved and daytime sleep was not disturbed.1

And in narcolepsy?

In 196 patients the time staying awake lengthened by 1.3 minutes (lower study dose) and 2.6 minutes (higher), while it fell by 1.9 minutes with placebo. The gap between the two doses was small.2

Which interactions have been measured?

After several weeks of dosing midazolam exposure fell by 17 percent (vein) and 32 percent (mouth), a sign of more CYP3A4 activity. Omeprazole rose by 38 percent because CYP2C19 is inhibited. Caffeine was unchanged. Anyone using drugs broken down by these enzymes should clarify this with a doctor.4

What do the long-term data show?

In the open-label extension with 743 patients over at least 12 months the effect was maintained. 13 percent stopped because of side effects, most often headache (25 percent) and insomnia (14 percent). Blood pressure and pulse rose moderately, mostly in the first three months.5

Does armodafinil work like a stimulant?

It acts on the dopamine transporter like cocaine but inhibits it less potently. In mice dopamine in the nucleus accumbens rose less strongly but for longer. In a discrimination test both enantiomers fully substituted for cocaine in mice. A potential for misuse can therefore not be ruled out.6

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

CYP2C19
A liver enzyme that breaks down drugs such as omeprazole and diazepam. If it is inhibited, their levels rise.
CYP3A4
The most important breakdown enzyme in the liver. If it is induced, other drugs broken down by it act more weakly.
Dopamine transporter (DAT)
A pump that takes dopamine back into the nerve cell. If it is inhibited, more dopamine stays between the cells.
Enantiomer
One of two mirror-image forms of the same molecule. The body can break them down at different speeds.
Half-life
The time until the amount in the blood has fallen by half.
Narcolepsy
A disorder with severe daytime sleepiness and sudden sleep attacks.
Racemate
A 50:50 mix of both mirror-image forms, as in modafinil.
Shift work disorder
Persistent sleepiness during working hours and poor sleep afterwards from night or rotating shifts.
Sleep latency
Time until falling asleep in the sleep lab. The shorter it is, the sleepier someone is.
Wakefulness latency
In the maintenance of wakefulness test, the time someone can stay awake in a quiet room.

Důkazy

Zdroje

Show all 10 sourcesHide sources 5 Studies1 Trial registry4 Database checked 26 Oct 2026

Studies

  1. Shift work disorder: wakefulness, memory and attention on the night shift

    Czeisler et al., Mayo Clinic Proceedings, 2009

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Narcolepsy: two doses versus placebo over 12 weeks

    Harsh et al., Current Medical Research and Opinion, 2006

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Same half-life, different curve: armodafinil versus modafinil

    Darwish et al., Clinical Drug Investigation, 2009

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Interactions at CYP1A2, CYP3A4 and CYP2C19

    Darwish et al., Clinical Pharmacokinetics, 2008

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. R-modafinil at the dopamine transporter

    Loland et al., Biological Psychiatry, 2012

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials with armodafinil on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Long-term study over at least 12 months (PubMed record)

    Black et al., Journal of Clinical Sleep Medicine, 2010 (DOI 10.5664/jcsm.27935 laut Crossref)

    Checked 26 Oct 2026 via PubMed, Crossref, doi.org
  2. US prescribing information for armodafinil (side effects, pharmacokinetics)

    DailyMed, U.S. National Library of Medicine (NDA 021875, Stand 2022)

    Checked 26 Oct 2026 via openFDA Label API, DailyMed
  3. US approval of armodafinil (NDA 021875, 15 Jun 2007)

    Drugs@FDA, U.S. Food and Drug Administration

    Checked 26 Oct 2026 via openFDA-API
  4. Armodafinil in ChEMBL (mechanism and approval)

    ChEMBL, EMBL-EBI (CHEMBL1201192)

    Checked 26 Oct 2026 via ChEMBL

V obchodě

Armodafinil (Nuvigil, Waklert) in the catalog

Velikosti, ceny a doby odeslání najdete na stránce produktu.

K produktu